NMD_Logo3_reg.jpg
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
June 18, 2024 01:00 ET | NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
June 13, 2024 08:00 ET | Umoja Biopharma, Inc.
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
Cellectis Logo.png
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
June 12, 2024 16:30 ET | Cellectis Inc.
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Rapport_Logo_Color_RGB.png
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
June 12, 2024 16:01 ET | Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
barinthuslogo.jpg
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024 16:01 ET | Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Tevogen Logo Notified.png
Tevogen Bio Set to Join Russell 3000® Index
June 12, 2024 15:45 ET | Tevogen Bio Inc
Tevogen Bio is set to join the Russell 3000® Index effective at the open of US equity markets on Monday, July 1.
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
June 12, 2024 08:00 ET | Quoin Pharmaceuticals, Inc.
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles...
OBI Logo.jpg
浩鼎啟動OBI-992一/二期臨床試驗
June 12, 2024 05:55 ET | OBI Pharma Inc.
OBI-992以TROP2為標靶的ADC 研究目的在評估治療多種實體腫瘤的安全性和有效性 台灣台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎 (4174.TWO)今(12)日宣布,正式啟動OBI-992的人體一/二期臨床試驗。OBI-992係浩鼎自行研發,以TROP2為標靶所設計的抗體藥物複合體(antibody-drug conjugate,...
OBI Logo.jpg
浩鼎启动OBI-992一/二期临床试验
June 12, 2024 05:55 ET | OBI Pharma Inc.
OBI-992以TROP2为标靶的ADC 研究目的在评估治疗多种实体肿瘤的安全性和有效性 台湾台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎 (4174.TWO)今(12)日宣布,正式启动OBI-992的人体一/二期临床试验。 OBI-992系浩鼎自行研发,以TROP2为标靶所设计的抗体药物复合体(antibody-drug...